Powering the Immune System to Transform Lives

Our Pipeline

A Deep, Broad Pipeline to Address Unmet Patient Need

Our deep and broad pipeline contains multiple clinical-stage and preclinical candidates for diseases with significant unmet patient need. We are moving with urgency to develop transformative medicines that have the potential to help improve the lives of millions of people around the world.

Hepatitis Delta

tobevibart ± elebsiran

Collaborator:: Alnylam
Treatment Type:: Treatment
Phase:: Phase 2,75%

Learn more about our therapeutic focus on Hepatitis Delta

Hepatitis B

tobevibart + elebsiran ± PEG-IFN-α

Collaborator:: Alnylam
Treatment Type:: Treatment
Phase:: Phase 2,75%

Learn more about our therapeutic focus on Hepatitis B

Solid Tumors

VIR-5818 (HER2) ± pembrolizumab

Treatment Type:: Treatment
Phase:: Phase 1,100%

VIR-5500 (PSMA)

Treatment Type:: Treatment
Phase:: Phase 1,100%

VIR-5525 (EGFR)

Treatment Type:: Treatment
Phase:: Pre-clinical,100%

Learn more about our therapeutic focus on Oncology

RSV

Preclinical antibody candidates*

Collaborator:: GSK
Treatment Type:: Prevention
Phase:: Pre-clinical,100%

Learn more about our therapeutic focus on RSV

HIV Cure

Preclinical antibody candidates

Collaborator:: Bill & Melinda Gates Foundation
Treatment Type:: Treatment
Phase:: Pre-clinical,100%

Learn more about our therapeutic focus on HIV

HIV: Human Immunodeficiency Virus; RSV: Respiratory Syncytial Virus; MPV: human Metapneumovirus; PEG-IFN-α: peg-interferon alfa-2a; mAb: monoclonal antibody. Tobevibart incorporates Xencor’s Xtend^TM and other Fc technologies.
*Per the collaboration agreement announced in February 2021, Vir and GSK are continuing to advance new monoclonal antibody therapeutics for RSV